» Articles » PMID: 20507236

ACE2 Overexpression Ameliorates Left Ventricular Remodeling and Dysfunction in a Rat Model of Myocardial Infarction

Abstract

The purpose of this study was to test the hypothesis that overexpression of angiotensin-converting enzyme 2 (ACE2) may favorably affect left ventricular (LV) remodeling and function after myocardial infarction (MI). The left anterior descending coronary artery was ligated to produce anterior MI in 100 Wistar-Kyoto rats that were randomly divided into Ad-ACE2, Ad-ACE2+A779, Ad-EGFP, model, and sham groups. Two weeks later, rats in the Ad-ACE2 and Ad-EGFP groups received direct intramyocardial injection of Ad-ACE2 and Ad-EGFP, respectively. Rats in the Ad-ACE2+A779 group received both intramyocardial injection of Ad-ACE2 and a continuous intravenous infusion of A779 for 15 days. LV volume and systolic function, the extent of myocardial fibrosis, and levels of ACE2, angiotensin II (Ang II), and collagen I protein expression were evaluated. Four weeks after ACE2 gene transfer, the Ad-ACE2 group showed reduced LV volume, extent of myocardial fibrosis, and expression levels of ACE, Ang II, and collagen I in the myocardium, and increased LV ejection fraction and levels of ACE2 activity and expression in comparison with the Ad-EGFP and model groups. These results suggest that ACE2 overexpression attenuated LV fibrosis and improved LV remodeling and systolic function. In conclusion, overexpression of ACE2 favorably affected the pathological process of LV remodeling after MI by inhibiting ACE activity, reducing AngII levels, and up-regulating Ang-(1-7) expression, thus providing a potential therapeutic target in the treatment of heart failure.

Citing Articles

Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions.

Kamdar A, Sykes R, Thomson C, Mangion K, Ang D, Lee M Infect Med (Beijing). 2024; 3(4):100147.

PMID: 39649442 PMC: 11621938. DOI: 10.1016/j.imj.2024.100147.


Pharmacologic Activation of Angiotensin-Converting Enzyme II Alleviates Diabetic Cardiomyopathy in db/db Mice by Reducing Reactive Oxidative Stress.

Kim D, Jeong W, Kim Y, Lee J, Cho S, Oh C Diabetes Metab J. 2023; 47(4):487-499.

PMID: 37096378 PMC: 10404524. DOI: 10.4093/dmj.2022.0125.


Effect of olmesartan and amlodipine on serum angiotensin-(1-7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension.

Kim K, Moon J, Ahn C, Lim S Diabetol Metab Syndr. 2023; 15(1):43.

PMID: 36899369 PMC: 10005920. DOI: 10.1186/s13098-023-00987-1.


Alamandine alleviated heart failure and fibrosis in myocardial infarction mice.

Zhao K, Xu T, Mao Y, Wu X, Hua D, Sheng Y Biol Direct. 2022; 17(1):25.

PMID: 36167556 PMC: 9516792. DOI: 10.1186/s13062-022-00338-6.


The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis.

Dorr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Poglitsch M Front Med (Lausanne). 2022; 9:878730.

PMID: 35559350 PMC: 9086596. DOI: 10.3389/fmed.2022.878730.